NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy

Tucson, AZ, September 09, 2021 --( PR.com )-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer affecting about 50,000 patients each year in the US. Click here to read more. TUCSON, AZ, July 15, 2026 — NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track Tucson, Arizona — April 30, 2026 — NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positi Tucson, AZ – April 22, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”), a clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics, today announce

The release as fetched from its publisher. nuvoxtherapeutics.com ↗